624 related articles for article (PubMed ID: 27252511)
1. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
Zahr AA; Salama ME; Carreau N; Tremblay D; Verstovsek S; Mesa R; Hoffman R; Mascarenhas J
Haematologica; 2016 Jun; 101(6):660-71. PubMed ID: 27252511
[TBL] [Abstract][Full Text] [Related]
2. Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications.
Nazha A; Khoury JD; Rampal RK; Daver N
Oncologist; 2015 Oct; 20(10):1154-60. PubMed ID: 26304912
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
Fisher DAC; Fowles JS; Zhou A; Oh ST
Front Immunol; 2021; 12():683401. PubMed ID: 34140953
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
Selicean SE; Tomuleasa C; Grewal R; Almeida-Porada G; Berindan-Neagoe I
Leuk Lymphoma; 2019 Apr; 60(4):876-885. PubMed ID: 30277128
[TBL] [Abstract][Full Text] [Related]
6. Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines.
Bock O; Höftmann J; Theophile K; Hussein K; Wiese B; Schlué J; Kreipe H
Am J Pathol; 2008 Apr; 172(4):951-60. PubMed ID: 18349123
[TBL] [Abstract][Full Text] [Related]
7. Primary myelofibrosis and its targeted therapy.
Shantzer L; Berger K; Pu JJ
Ann Hematol; 2017 Apr; 96(4):531-535. PubMed ID: 27539616
[TBL] [Abstract][Full Text] [Related]
8. A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
Garmezy B; Schaefer JK; Mercer J; Talpaz M
Blood Rev; 2021 Jan; 45():100691. PubMed ID: 32354563
[TBL] [Abstract][Full Text] [Related]
9. CDK6 Is a Therapeutic Target in Myelofibrosis.
Dutta A; Nath D; Yang Y; Le BT; Mohi G
Cancer Res; 2021 Aug; 81(16):4332-4345. PubMed ID: 34145036
[TBL] [Abstract][Full Text] [Related]
10. Myelofibrosis: clinicopathologic features, prognosis, and management.
O'Sullivan JM; Harrison CN
Clin Adv Hematol Oncol; 2018 Feb; 16(2):121-131. PubMed ID: 29741513
[TBL] [Abstract][Full Text] [Related]
11. IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis.
Longhitano L; Tibullo D; Vicario N; Giallongo C; La Spina E; Romano A; Lombardo S; Moretti M; Masia F; Coda ARD; Venuto S; Fontana P; Parenti R; Li Volti G; Di Rosa M; Palumbo GA; Liso A
Aging (Albany NY); 2021 Dec; 13(23):25055-25071. PubMed ID: 34905501
[TBL] [Abstract][Full Text] [Related]
12. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
[TBL] [Abstract][Full Text] [Related]
13. Biology and management of idiopathic myelofibrosis.
Smith BD; Moliterno AR
Curr Opin Oncol; 2001 Mar; 13(2):91-4. PubMed ID: 11224705
[TBL] [Abstract][Full Text] [Related]
14. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients.
Gianelli U; Fiori S; Cattaneo D; Bossi A; Cortinovis I; Bonometti A; Ercoli G; Bucelli C; Orofino N; Bulfamante G; Iurlo A
Histopathology; 2017 Dec; 71(6):897-908. PubMed ID: 28710830
[TBL] [Abstract][Full Text] [Related]
16. TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche.
Yao JC; Oetjen KA; Wang T; Xu H; Abou-Ezzi G; Krambs JR; Uttarwar S; Duncavage EJ; Link DC
J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35439167
[TBL] [Abstract][Full Text] [Related]
17. Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis.
Hussein K; Stucki-Koch A; Alchalby H; Triviai I; Kröger N; Kreipe H
Biol Blood Marrow Transplant; 2016 Apr; 22(4):644-650. PubMed ID: 26708839
[TBL] [Abstract][Full Text] [Related]
18. New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.
Palandri F; Auteri G; Baccarani M
Hematol Oncol; 2017 Jun; 35(2):145-150. PubMed ID: 27510853
[TBL] [Abstract][Full Text] [Related]
19. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development.
Gastinne T; Vigant F; Lavenu-Bombled C; Wagner-Ballon O; Tulliez M; Chagraoui H; Villeval JL; Lacout C; Perricaudet M; Vainchenker W; Benihoud K; Giraudier S
Exp Hematol; 2007 Jan; 35(1):64-74. PubMed ID: 17198875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
